Key Highlights

  • Centene (NYSE:CNC) reports before the open on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 0.10 per share, close to management's near-breakeven signal, against 2026 guidance of more than USD 4.80.
  • Chemed (NYSE:CHE) reports after the close the same day, with consensus adjusted earnings of USD 6.44 per share and a raised 2026 range of USD 25.00 to USD 25.75 already set by its July release.
  • NRC Health (NASDAQ:NRC) also reports after the close against consensus earnings of USD 0.21 per share, with total recurring contract value up 11% to USD 151.9 million and no formal guidance on offer.
  • Medical cost trends and government-set payment rates link the three, and the Federal Reserve decides on Wednesday, October 28, 2026, after raising rates to a range of 3.75% to 4.00% on Wednesday, September 16, 2026.

Centene (NYSE:CNC): medical cost ratios and Medicaid membership

Centene (NYSE:CNC), a managed care company covering Medicaid, Medicare and Affordable Care Act marketplace members, reports third-quarter results before the open on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 0.10 per share. In its report of Tuesday, July 28, 2026, the company earned USD 2.51 per share and raised 2026 adjusted earnings guidance to more than USD 4.80 from more than USD 3.40, including a USD 0.50 per share prior-period benefit that will not recur. Management guided to near-breakeven earnings in the third quarter and a loss in the fourth, a seasonal pattern similar to 2025, so the consensus sits close to the company's own signal.

The health benefit ratio, which is medical claims as a share of premiums, moves earnings. It improved to 89.6% in the second quarter from 93.0%, with the marketplace ratio at 79.2% from 90.6%, helped by a USD 180 million favourable 2025 risk adjustment settlement. Debt to capital improved to 41.6% from 46.5% at the end of 2025. The Medicare ratio was 89.5% and the Medicaid ratio 93.9%, the highest of the three. Medicaid membership was 12.1 million, with the full-year decline now expected at 8% to 9%, against 6% before. The bull case is a result above breakeven with guidance above USD 4.80 confirmed. The bear case is higher Medicaid costs, faster membership losses or reversing settlements. The shares fell after the July beat, according to market data, so a strong quarter may already be priced in.

Chemed (NYSE:CHE): hospice census against fixed daily rates

Chemed (NYSE:CHE) owns Vitas, a hospice and palliative care provider, and Roto-Rooter, a plumbing and drain cleaning business, and it reports third-quarter results after the close on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 6.44 per share. In the company's release of Wednesday, July 29, 2026, second-quarter earnings rose about 43.7% on a hospice rebound, and full-year adjusted earnings guidance was lifted to USD 25.00 to USD 25.75 per share, against an earlier consensus near USD 24.34. Results cannot be known in advance.

Vitas earns fixed daily Medicare payment rates, so admissions and length of stay matter more than price, and a higher patient census lifts margins because staffing costs are largely fixed. The Centers for Medicare and Medicaid Services sets the annual rate update, which makes reimbursement policy the reference point. The bull case is earnings above USD 6.44 with census growth sustained and guidance lifted toward the top of the range, which would likely draw a favourable response. The bear case is a result that only meets consensus with the range held, or slower admissions, since a raised outlook leaves less room for disappointment. Roto-Rooter adds weather and housing exposure and could cap the result through job counts or labour costs. The company has a market value near USD 6.79 billion.

NRC Health (NASDAQ:NRC): recurring contract value and hospital budgets

NRC Health (NASDAQ:NRC) sells subscription analytics that measure patient and member experience for hospitals and other care providers, and it reports after the close on Tuesday, October 27, 2026. Consensus earnings are USD 0.21 per share. Second-quarter revenue, reported on Tuesday, July 28, 2026, was USD 35.4 million, up 4%, and the GAAP net loss was USD 3.3 million, or USD 0.15 per share, after about USD 2.9 million of accelerated stock vesting and related cash bonuses. Adjusted earnings were USD 0.31 per share, so investors will check whether the USD 0.21 estimate uses a GAAP or adjusted basis.

Total recurring contract value, the annualised value of subscriptions in force, rose 11% to USD 151.9 million and is the best guide to future revenue. Hospital budgets, which depend on reimbursement, fund those contracts, and a quarterly dividend of USD 0.16 was payable on Friday, October 9, 2026. The company gives no formal guidance, though management cited the strongest bookings in seven years for The Governance Institute, a board education unit. The bull case is contract value growth near 11% with margins recovering as the charges drop out. The bear case is slower bookings or revenue growth near 4% with rising expenses. The shares fell after the second-quarter report despite the contract value growth, which shows how sensitive the reaction is to margins.

Where Things Stand

The answer is that all three need evidence that cost trends and reimbursement are holding up, but each is tested on a different number. Centene (NYSE:CNC) needs a near-breakeven quarter and confirmation of guidance above USD 4.80 once the one-time benefit is removed. Chemed (NYSE:CHE) needs hospice census growth that supports the raised USD 25.00 to USD 25.75 range, and NRC Health (NASDAQ:NRC) needs recurring contract value to keep growing near 11% while margins recover. Medicaid claims, fixed Medicare daily rates and hospital budgets are all shaped by government payment decisions, so a shift in policy or in cost trends would reach the three through different channels but in the same direction.

The next catalysts are the Centene release before the open and the Chemed and NRC Health releases after the close on Tuesday, October 27, 2026, followed by the Federal Reserve decision on Wednesday, October 28, 2026, a day after the reports. Guidance changes at Centene and Chemed and the tone on bookings at NRC Health are likely to matter more than the quarterly per share figures. Consensus figures are estimates, not guarantees, medical cost trends can shift quickly, and this is not investment advice.